Abbott ’s reported third-quarter 2020 global sales of $8.9bn beat Wall Street estimates by $314m, driven by its strong position in COVID-19 tests, which reached $881m in sales this quarter, and a strong return in medtech sales, particularly in diabetes care.
After a tough second quarter, the company’s third-quarter sales rose 9.6% from $8
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?